Linaclotide
FDA-approved product (capsule, oral), marketed as Linaclotide, Linzess.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Constipation
- Constipation disorder
- Irritable bowel syndrome
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other drugs for constipation
- FDA pharmacologic class
- Guanylate Cyclase-C Agonist FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA74.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli60.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae56.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis57.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Linaclotide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- TicagrelorExisting use: Acute coronary syndrome, Acute myocardial infarction, Coronary artery disease and 6 more62.1% AI-predicted activityagainst MRSA50+ registered studies
- Edoxaban TosylateExisting use: Atrial fibrillation, Deep vein thrombosis, Pulmonary embolism and 3 more62.1% AI-predicted activityagainst MRSA22 registered studies
- CrizotinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma62.0% AI-predicted activityagainst MRSA50+ registered studies
- Montelukast SodiumExisting use: Airway obstruction, Allergic rhinitis, Asthma and 2 more62.0% AI-predicted activityagainst MRSA50+ registered studies
- GrazoprevirExisting use: Chronic hepatitis C virus infection61.9% AI-predicted activityagainst MRSA50+ registered studies
- Octreotide AcetateExisting use: Acromegaly, Carcinoid tumor, Metastasis and 1 more61.7% AI-predicted activityagainst MRSA50+ registered studies
- CyclosporineExisting use: Conjunctivitis, Corneal disease, Eye disease and 6 more61.7% AI-predicted activityagainst MRSA50+ registered studies
- AnidulafunginExisting use: Candidemia, Candidiasis, Peritonitis61.6% AI-predicted activityagainst MRSA43 registered studies
- Triptorelin PamoateExisting use: Central precocious puberty, Metastatic prostate cancer, Neoplasm and 3 more61.6% AI-predicted activityagainst MRSA50+ registered studies
- Vinblastine SulfateExisting use: Classic Hodgkin lymphoma, Fungal infectious disease, Hodgkins lymphoma and 3 more61.5% AI-predicted activityagainst MRSA50+ registered studies
- Lenacapavir SodiumExisting use: HIV infection, HIV-1 infection, Viral disease61.5% AI-predicted activityagainst MRSANo documented evidence found
- Setmelanotide AcetateExisting use: Obesity61.5% AI-predicted activityagainst MRSANo documented evidence found
Registered studies
A registration describes a study; it does not establish a positive result.
Single-dose Linaclotide for Capsule Endoscopy Preparation
NCT02465385 · start 2015-02
Registered record
- Registry ID
- NCT02465385
- Conditions
- Crohn's; Ulcerative Colitis; Gastrointestinal Bleeding
- Interventions
- Linaclotide
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2015-02
- Completion
- 2016-06
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCrohn's; Ulcerative Colitis; Gastrointestinal BleedingInterventionLinaclotidePhasePhase 4Registry statusCompletedPhase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome
NCT02316899 · start 2014-10-21
Registered record
- Registry ID
- NCT02316899
- Conditions
- Irritable Bowel Syndrome With Constipation (IBS-C)
- Interventions
- linaclotide; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2014-10-21
- Completion
- 2016-03-29
- Enrolment
- 500
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIrritable Bowel Syndrome With Constipation (IBS-C)Interventionlinaclotide; PlaceboPhasePhase 3Registry statusCompletedTrial of Linaclotide in Patients With Chronic Idiopathic Constipation
NCT02291679 · start 2014-10
Registered record
- Registry ID
- NCT02291679
- Conditions
- Chronic Idiopathic Constipation
- Interventions
- Linaclotide; Matching Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2014-10
- Completion
- 2015-08
- Enrolment
- 1,223
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Idiopathic ConstipationInterventionLinaclotide; Matching PlaceboPhasePhase 3Registry statusCompletedA Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide Therapeutically
NCT02220348 · start 2014-07-31
Registered record
- Registry ID
- NCT02220348
- Conditions
- Breast Feeding; Constipation; Irritable Bowel Syndrome
- Interventions
- linaclotide
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2014-07-31
- Completion
- 2019-05-31
- Enrolment
- 7
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast Feeding; Constipation; Irritable Bowel SyndromeInterventionlinaclotidePhasePhase 1Registry statusCompletedEffect to Linaclotide on Colonic Motility
NCT06989268 · start 2014-02-10
Registered record
- Registry ID
- NCT06989268
- Conditions
- Chronic Constipation
- Interventions
- Linaclotide 290 micrograms; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2014-02-10
- Completion
- 2015-06-03
- Enrolment
- 10
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic ConstipationInterventionLinaclotide 290 micrograms; PlaceboPhasePhase 4Registry statusCompletedInvestigation of Linaclotide's Effect on the Bi-directional Brain and Gut Axis in IBS-C Patients
NCT02078323 · start 2014-02
Registered record
- Registry ID
- NCT02078323
- Conditions
- Irritable Bowel Syndrome With Constipation (IBS-C)
- Interventions
- Linaclotide; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2014-02
- Completion
- 2018-07-20
- Enrolment
- 39
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIrritable Bowel Syndrome With Constipation (IBS-C)InterventionLinaclotide; PlaceboPhaseNot applicableRegistry statusCompletedLinaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers
NCT01950403 · start 2013-09
Registered record
- Registry ID
- NCT01950403
- Conditions
- Colorectal Cancer; Healthy, no Evidence of Disease
- Interventions
- linaclotide acetate; placebo; pharmacological study; laboratory biomarker analysis
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2013-09
- Completion
- 2018-02-22
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionColorectal Cancer; Healthy, no Evidence of DiseaseInterventionlinaclotide acetate; placebo; pharmacological study; laboratory biomarker analysisPhasePhase 1Registry statusCompletedA Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome
NCT01714843 · start 2012-08-10
Registered record
- Registry ID
- NCT01714843
- Conditions
- Constipation-predominant Irritable Bowel Syndrome (IBS-C)
- Interventions
- linaclotide; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2012-08-10
- Completion
- 2013-12-07
- Enrolment
- 559
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionConstipation-predominant Irritable Bowel Syndrome (IBS-C)Interventionlinaclotide; placeboPhasePhase 2Registry statusCompletedSafety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating
NCT01642914 · start 2012-08
Registered record
- Registry ID
- NCT01642914
- Conditions
- Chronic Constipation; Constipation
- Interventions
- Linaclotide 290 micrograms; Linaclotide 145 micrograms; Matching placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-08
- Completion
- 2013-08
- Enrolment
- 487
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Constipation; ConstipationInterventionLinaclotide 290 micrograms; Linaclotide 145 micrograms; Matching placeboPhasePhase 3Registry statusCompletedA Safety and Pharmacokinetics Study of ASP0456 in Healthy Subjects
NCT01279915 · start 2010-10
Registered record
- Registry ID
- NCT01279915
- Conditions
- Healthy; Pharmacokinetics of ASP0456
- Interventions
- ASP0456; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2010-10
- Completion
- 2011-01
- Enrolment
- 32
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy; Pharmacokinetics of ASP0456InterventionASP0456; PlaceboPhasePhase 1Registry statusCompletedTrial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
NCT00938717 · start 2009-07
Registered record
- Registry ID
- NCT00938717
- Conditions
- Irritable Bowel Syndrome With Constipation
- Interventions
- Linaclotide or Matching Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2009-07
- Completion
- 2010-09
- Enrolment
- 805
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIrritable Bowel Syndrome With ConstipationInterventionLinaclotide or Matching PlaceboPhasePhase 3Registry statusCompletedTrial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation
NCT00948818 · start 2009-07
Registered record
- Registry ID
- NCT00948818
- Conditions
- Irritable Bowel Syndrome Characterized by Constipation
- Interventions
- Linaclotide 290 micrograms; Matching placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2009-07
- Completion
- 2010-08
- Enrolment
- 803
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIrritable Bowel Syndrome Characterized by ConstipationInterventionLinaclotide 290 micrograms; Matching placeboPhasePhase 3Registry statusCompletedAn Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation
NCT00765999 · start 2008-10-31
Registered record
- Registry ID
- NCT00765999
- Conditions
- Chronic Constipation; Irritable Bowel Syndrome With Constipation
- Interventions
- Linaclotide
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2008-10-31
- Completion
- 2012-01-31
- Enrolment
- 1,559
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Constipation; Irritable Bowel Syndrome With ConstipationInterventionLinaclotidePhasePhase 3Registry statusCompletedAn Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation
NCT00730171 · start 2008-09
Registered record
- Registry ID
- NCT00730171
- Conditions
- Irritable Bowel Syndrome With Constipation; Chronic Constipation
- Interventions
- Linaclotide
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2008-09
- Completion
- 2012-03
- Enrolment
- 1,743
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIrritable Bowel Syndrome With Constipation; Chronic ConstipationInterventionLinaclotidePhasePhase 3Registry statusCompletedPhase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation
NCT00765882 · start 2008-09
Registered record
- Registry ID
- NCT00765882
- Conditions
- Chronic Constipation
- Interventions
- Linaclotide 290 micrograms; Linaclotide 145 micrograms; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2008-09
- Completion
- 2009-08
- Enrolment
- 633
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic ConstipationInterventionLinaclotide 290 micrograms; Linaclotide 145 micrograms; PlaceboPhasePhase 3Registry statusCompleted